WhiteSwell Announces Successful Treatment of Acute Decompensated Heart Failure Patients in its Early Feasibility DELTA-HF Study finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
With VP Clinical and VP Technical Operations, Company is Well Positioned for Next Phase of Growth WhiteSwell, a company pioneering new ways to treat acute decompensated heart failure, announced today
(1)
Adds to Portfolio of 40 Patents for Catheter-Based Technology That Leverages Power of Body s Natural Fluid Removal Process
WhiteSwell, a company pioneering new ways to treat acute decompensated heart failure, announced today that the U.S. Patent and Trademark Office (USPTO) has granted the company a new patent for treating ADHF patients with a catheter technology designed to stimulate lymphatic drainage using a novel impeller pump combined with restrictors.
This patent grant, which is WhiteSwell s third this year, adds to its rapidly expanding U.S. patent portfolio covering a set of devices that leverage the lymphatic system s remarkable innate drainage properties for fluid-overloaded ADHF patients. WhiteSwell has received 10 patent grants from the U.S. PTO in the last two years, and has a U.S. portfolio of over 40 patents granted or pending.